Plant Name: Boswellia carterii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| GPBAR1; | |
| PTPN1; PTPN2; | |
| ACHE; | |
| TDP1; PTGES; PKM; HSD11B1; HSD17B1; ALOX15; NOX4; ALDH1A1; USP2; TNKS; TNKS2; | |
| CFTR; | |
| GSK3B; SYK; MAPK1; CDK6; FLT3; CDK8; CDK9; CSNK2A1; | |
| AR; NR3C2; PGR; NR3C1; | |
| PPARA; PPARD; | |
| ESR1; ESR2; | |
| NR1H4; | |
| ALOX5; MAOA; PTGS2; XDH; | |
| PREP; | |
| TLR2; | |
| HIF1A; TP53; | |
| SLC22A1; SLC22A3; | |
| ABCC1; ABCG2; | |
| RAB9A; NPC1; LMNA; FABP3; FABP5; SERPINA6; FABP2; FABP4; TTR; MAPT; THPO; SIGMAR1; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
| Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Serine protease | PREP | Prolyl endopeptidase | P48147 | CHEMBL3202 |
| SLC superfamily of solute carriers | SLC22A1 | Solute carrier family 22 member 1 | O15245 | CHEMBL5685 |
| SLC superfamily of solute carriers | SLC22A3 | Solute carrier family 22 member 3 | O75751 | CHEMBL2073673 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.649E-12 | 5.244E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.675E-12 | 9.830E-09 | AR, CDK8, CDK9, ESR1, ESR2, NR1H4, NR3C1, NR3C2, PGR, PPARA, PPARD |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.072E-10 | 8.116E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.894E-10 | 1.213E-07 | ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.734E-10 | 2.973E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.972E-09 | 8.765E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 4.419E-09 | 1.718E-06 | AR, CDK6, CFTR, CYP1B1, ESR1, GSK3B, MAPK1, NOX4, NR1H4, NR3C1, PKM, PPARD, PTGS2, TLR2, TP53, TSHR |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.456E-09 | 2.084E-06 | CFTR, HIF1A, MAPK1, NPC1, NPSR1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.407E-09 | 3.103E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.383E-08 | 4.856E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.408E-08 | 1.776E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 6.834E-08 | 1.830E-05 | ABCC1, ALOX15, ALOX5, SYK, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.592E-07 | 3.554E-05 | CYP1A2, CYP2C9, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 4.509E-07 | 8.465E-05 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HSD11B1, NOX4, NR3C2, PTGES, PTGS2, RAB9A, SIGMAR1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.577E-07 | 1.164E-04 | CDK6, CFTR, HIF1A, MAPK1, NPC1, NPSR1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 7.404E-07 | 1.286E-04 | AR, CDK6, CYP1B1, FABP3, LMNA, NOX4, PPARD, PTGES, PTGS2, PTPN2, TLR2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.583E-06 | 2.534E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 2.099E-06 | 3.223E-04 | CDK6, CDK9, GSK3B, HIF1A, MAPK1, MAPT, PTGS2, PTPN1, PTPN2, SYK, TP53, XDH |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.652E-06 | 5.299E-04 | AR, ESR1, ESR2, L3MBTL1, NR1H4, NR3C1, NR3C2, PGR, PPARA, PPARD, PTPN1, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.418E-06 | 6.089E-04 | CSNK2A1, HIF1A, MAPT, NR3C1 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 6.089E-06 | 7.987E-04 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 6.452E-06 | 8.363E-04 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 7.283E-06 | 9.328E-04 | ABCG2, ACHE, CSNK2A1, ESR1, ESR2, FLT3, L3MBTL1, MAPK1, MAPT, PGR, PKM, PTGS2, RAB9A, SLC22A1, TP53, TTR, USP2, XDH |
| BP | GO:0009987; cellular process | GO:0030518; intracellular steroid hormone receptor signaling pathway | 7.488E-06 | 9.371E-04 | AR, ESR1, ESR2, NR3C1, PGR |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 8.564E-06 | 1.050E-03 | CFTR, GSK3B, MAPK1, NOX4, NR1H4, PKM, PTGS2, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 8.581E-06 | 1.050E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 8.698E-06 | 1.058E-03 | CSNK2A1, CYP1B1, ESR1, FABP4, GSK3B, MAPT, NR1H4, PPARA, PTGS2, PTPN1, PTPN2, RAB9A, SERPINA6, TNKS, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.185E-05 | 1.410E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.510E-05 | 1.703E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.163E-05 | 2.331E-03 | ALOX15, ALOX5, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 2.163E-05 | 2.331E-03 | CDK8, CDK9, MAPK1 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 2.223E-05 | 2.373E-03 | MAPK1, MAPT, PPARA, PTPN1, SYK, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.620E-05 | 2.742E-03 | MAPK1, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 2.846E-05 | 2.927E-03 | CDK9, ESR1, GSK3B, HIF1A, MAPK1, NR3C1, PTPN1, PTPN2, SYK, TP53 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.043E-05 | 3.082E-03 | HIF1A, LMNA, PPARD, PTGS2, TP53 |
| BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 3.548E-05 | 3.496E-03 | AR, PGR |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.548E-05 | 3.496E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.548E-05 | 3.496E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.548E-05 | 3.496E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.548E-05 | 3.496E-03 | GPBAR1, NR1H4 |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 4.359E-05 | 4.153E-03 | CDK9, ESR1, PPARA |
| MF | GO:0140110; transcription regulator activity | GO:0001077; transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding | 4.399E-05 | 4.164E-03 | AR, ESR1, HIF1A, NR1H4, NR3C1, PGR, PPARA |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 4.752E-05 | 4.452E-03 | AR, CDK6, CSNK2A1, ESR1, FLT3, HIF1A, MAPK1, PPARD, PTGS2, SYK, THPO, TSHR |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.932E-05 | 4.570E-03 | CYP19A1, NR1H4, PPARA, PPARD, PTPN2 |
| BP | GO:0051179; localization | GO:0015844; monoamine transport | 5.073E-05 | 4.641E-03 | SLC22A1, SLC22A3, SYK |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 5.140E-05 | 4.683E-03 | AR, ESR1, GSK3B, PPARA, TP53 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.234E-05 | 4.729E-03 | ALOX5, AR, CDK6, CDK8, CDK9, CSNK2A1, ESR1, ESR2, FABP5, GSK3B, HIF1A, L3MBTL1, LMNA, MAPK1, NR1H4, NR3C1, NR3C2, PGR, PPARA, PPARD, PTPN2, TNKS, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 5.400E-05 | 4.859E-03 | CDK6, CFTR, CYP1B1, MAPK1, NR3C1, PTGS2, TP53 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 5.646E-05 | 5.059E-03 | CSNK2A1, ESR1, GSK3B, PGR, PPARA, TP53, USP2 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 5.716E-05 | 5.080E-03 | AR, CYP1B1, ESR1, ESR2, MAPK1, NR1H4, SYK, TLR2 |
| MF | Unclassified; | GO:0004872; receptor activity | 6.269E-05 | 5.439E-03 | AR, ESR1, ESR2, FLT3, GPBAR1, NPC1, NPSR1, NR1H4, NR3C1, NR3C2, PGR, PPARA, PPARD, SIGMAR1, TLR2, TSHR |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 6.469E-05 | 5.567E-03 | ALOX15, AR, FLT3, MAPK1, NOX4, PTPN1, SYK, THPO, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.722E-05 | 5.762E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 7.080E-05 | 5.906E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 7.080E-05 | 5.906E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.080E-05 | 5.906E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.080E-05 | 5.906E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 7.080E-05 | 5.906E-03 | ALDH1A1, AR |
| BP | GO:0051179; localization | GO:0006855; drug transmembrane transport | 7.182E-05 | 5.946E-03 | ABCC1, ABCG2, SLC22A1, SLC22A3 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 8.211E-05 | 6.502E-03 | CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 8.686E-05 | 6.804E-03 | HIF1A, PPARD, TP53 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 9.208E-05 | 7.110E-03 | ABCG2, ACHE, AR, CDK6, CDK8, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, ESR1, ESR2, FABP4, FLT3, GSK3B, HIF1A, L3MBTL1, LMNA, MAOA, MAPK1, MAPT, NOX4, NPC1, NR3C1, PKM, PPARA, PPARD, PREP, PTGS2, PTPN1, PTPN2, RAB9A, SIGMAR1, SYK, TDP1, TLR2, TNKS, TNKS2, TP53, XDH |
| BP | GO:0051179; localization | GO:0015711; organic anion transport | 9.607E-05 | 7.340E-03 | ABCC1, CFTR, FABP3, NR1H4, PPARA, PPARD, SLC22A1, SLC22A3 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 9.795E-05 | 7.406E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 9.859E-05 | 7.429E-03 | HIF1A, MAPK1, MAPT, NPC1, PPARA, PTGS2, TLR2, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.099E-04 | 8.086E-03 | CYP1B1, HIF1A, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.177E-04 | 8.517E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.228E-04 | 8.796E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.228E-04 | 8.796E-03 | MAPT, PTPN1, TP53 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 1.355E-04 | 9.639E-03 | ACHE, CSNK2A1, FLT3, L3MBTL1, MAPT, PKM, PPARA, PTPN1, PTPN2, SYK, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0035774; positive regulation of insulin secretion involved in cellular response to glucose stimulus | 1.366E-04 | 9.660E-03 | CFTR, HIF1A, NR1H4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 7.378E-15 | 3.213E-11 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4, NR3C1, NR3C2, PGR, SERPINA6 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.019E-10 | 4.920E-08 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.013E-10 | 7.346E-08 | HSD11B1; HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.591E-08 | 8.645E-07 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.965E-08 | 1.945E-06 | CYP2C9; ALOX5; ALOX15; CYP2C19; PTGS2; PTGES |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.422E-08 | 2.560E-06 | CYP2C9; MAOA; ALOX5; ALOX15; MAPK1; CYP2C19; PTGS2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.044E-08 | 1.648E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.605E-07 | 3.270E-06 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.142E-07 | 2.659E-06 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.378E-06 | 4.178E-05 | MAOA; ALOX15; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD11B1; CYP2C9; PKM; HSD17B1; ALOX5; CYP1A2; ALDH1A1; CYP1A1; XDH; PTGES |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.760E-06 | 7.346E-05 | AR; GSK3B; CDK6; FLT3; MAPK1; PTGS2; HIF1A; TP53; PPARD |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.981E-06 | 4.418E-05 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.563E-06 | 4.178E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.451E-06 | 4.688E-05 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.284E-06 | 7.316E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; TLR2 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.978E-06 | 4.988E-05 | SLC22A1; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.735E-05 | 4.540E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.599E-06 | 9.779E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 9.970E-05 | 9.028E-04 | GSK3B; MAPK1; ESR1; ESR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.267E-04 | 1.848E-03 | GSK3B; AR; MAPK1; TP53 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.679E-04 | 2.856E-03 | SLC22A3; SLC22A1; MAPK1; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.759E-04 | 3.373E-03 | ABCC1; CDK6; CYP1B1; MAPK1; PTGS2; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.945E-04 | 4.038E-03 | MAPK1; TP53; HIF1A; ESR1; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.215E-04 | 4.052E-03 | CDK6; PKM; SYK; MAPK1; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 9.785E-04 | 5.317E-03 | GSK3B; CDK6; SYK; MAPK1; TP53; TLR2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.036E-03 | 5.447E-03 | GSK3B; MAPK1; PPARA; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.320E-03 | 6.487E-03 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.773E-04 | 5.107E-03 | CDK6; MAPK1; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.462E-03 | 6.621E-03 | CDK6; MAPK1; TP53; TLR2 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 7.062E-04 | 4.427E-03 | GSK3B; MAPK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.773E-04 | 5.107E-03 | FABP4; PTGS2; TSHR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 9.239E-04 | 5.193E-03 | FLT3; MAPK1; PPARD |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.353E-03 | 6.487E-03 | CDK6; MAPK1; TP53 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 4.314E-04 | 3.196E-03 | ABCC1; CFTR; ABCG2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.180E-03 | 6.010E-03 | GSK3B; MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.414E-03 | 6.586E-03 | CDK6; MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.890E-03 | 7.703E-03 | GSK3B; SYK; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.745E-03 | 7.689E-03 | CDK6; MAPK1; TP53 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.471E-03 | 1.588E-02 | MAPK1; PPARA; CFTR; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 4.714E-03 | 1.635E-02 | GSK3B; SYK; CSNK2A1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.890E-03 | 7.703E-03 | CDK6; MAPK1; TP53 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.890E-03 | 7.703E-03 | MAPK1; PTGS2; TLR2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.481E-03 | 1.588E-02 | MAPK1; ESR1; ESR2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.016E-03 | 1.170E-02 | CDK6; PTGS2; TP53 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.965E-03 | 7.814E-03 | PTPN1; CSNK2A1; MAPK1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.761E-03 | 1.426E-02 | SYK; CSNK2A1; PTGS2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.857E-03 | 1.989E-02 | PTPN1; GSK3B; PPARA |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 7.290E-03 | 2.393E-02 | ALOX5; MAPK1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.634E-03 | 2.393E-02 | GSK3B; MAPK1; TP53 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 8.168E-03 | 2.475E-02 | AR; MAPK1; PGR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.634E-03 | 2.393E-02 | ABCC1; MAPK1; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.160E-02 | 3.206E-02 | LMNA; MAPK1; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.350E-03 | 2.475E-02 | GSK3B; CDK6; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.138E-02 | 3.199E-02 | PTPN1; GSK3B; MAPK1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.884E-02 | 4.874E-02 | GSK3B; MAPK1; MAPT |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.727E-02 | 4.615E-02 | MAPK1; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.782E-02 | 4.684E-02 | MAPK1; PTGS2 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.464E-02 | 3.979E-02 | GSK3B; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.129E-02 | 3.199E-02 | PKM; MAPK1 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 7.563E-03 | 2.393E-02 | MAPK1; NR3C2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 8.333E-03 | 2.475E-02 | MAPK1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.041E-02 | 3.029E-02 | CYP3A4; XDH |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.234E-03 | 1.568E-02 | MAPK1; TP53 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.098E-04 | 9.423E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; ABCC1; ABCC1; XDH |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA; PREP |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; PTGS2 |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; ESR1 |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; SERPINA6; NR3C1; NR3C1; NR3C1; NR3C1; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; ABCC1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; HSD11B1; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; NR3C2; XDH |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; NR3C1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; HSD11B1; HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; NR3C1 |
| N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| NA: NA | Obstructive airway diseases | NA | SERPINA6 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Non-infectious rhinitis | NA | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; NR3C1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; SYK; NR3C1; PTGS2; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGES; PTGS2; MAPT |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PGR; PTGS2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARD; PPARD |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; PREP |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| K00-K95: Diseases of the digestive system | Celiac disease | K90.0 | PREP |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; NR3C2 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2 |
| C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; NR3C1; PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; SERPINA6; NR3C1; PTGS2 |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | NR3C2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; SYK; HIF1A; TP53; PGR; FLT3; FLT3; ACHE; ESR1; ESR1; TLR2; NR3C2; NR3C1; PTGS2; MAPK1; CSNK2A1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; PPARD; NR3C2; NR3C1; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1; TLR2 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1; NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; TP53; FLT3; TLR2; PKM; MAPK1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT; PREP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; NR3C1; NR3C1; NR3C1 |
| N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA; NR3C1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | NR3C2 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Uterine fibroids | D25 | PGR |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1; TLR2 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; NR3C2; PREP |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |